Methods: In this study we analyzed the rate of postinterventional adverse cardiac events and the clinical and angiographic outcome after placement of 120 Sirius CarbostentsTM in 105 consecutive unselected patients (60.7+11.7 years, 79.8% male) between 2000 and 2002. Routine control angiography was not planned, but was scheduled in symptomatic patients or an unclear morphologic or functional situation.

Results: A total of 120 Sirius CarbostentsTM were implanted, in 20 patients additional 29 stents of other types. Indications for intervention were stable angina (57.1%) and acute coronary syndrome (42.9%) including ST-elevation infarction (22.9%). Multivessel disease was present in 71.2%. 50.4% of stenoses were classified as type C, complex stenoses were found in 51.4%, calcified lesions in 54.3%. In 30.5% a recanalization of occluded vessels were necessary. Angiographic success was 100%. As adverse events were documented: non-Q-wave-infarction (3.8%),and target vessel intervention (2.9%). Stent thrombosis did not occur. Clinical and angiographic assessment (39/105 patients) after six months showed a restenosis of 41%, target lesions intervention in 28.2%, angioplasty of a different lesion in 25.6%. Restenosis in those patients where only Sirius CarbostentsTM were implanted was 37.5%.